Bimeda has forged a joint venture firm in Shijiazhuang in northern China to develop and manufacture veterinary and animal health products for the Chinese and Asian regional market.

The 50-50 joint venture between Bimeda and Shijiazhuang Rainbow Laboratories will initially provide product stability and raw materials testing for the pharmaceutical industry. The state of the art facility operates to the principals of Good Laboratory practise (GLP) & is ISO 9001 accredited. FDA approval of the Laboratory is pending but is expected imminently. It will be the initial platform for expected further investment by Bimeda in the Chinese market. Employing twenty analysts developing new products, new raw materials for the multi-jurisdictions of the Bimeda brand ''The demand for animal health products in China will increase and this will lift the Chinese animal health market and other international veterinary markets in the region'' said Bimeda group chief executive Donal Tierney.